← Leaderboards
Charles F Landry
University Of Wisconsin Madison
$7,992,480
Attributed
$14,706,298
Total exposure
7
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,706,298 · 7
By mechanism
R44$13,094,303 · 5
R01$1,611,995 · 2
Top collaborators
- Frederick R Blattner14 shared
- Steven Joseph Darnell1 shared
- David A Frisch1 shared
Most similar at University Of Wisconsin Madison
Same institution · by research overlap
- Frederick R Blattner$30,522,424
- Joseph W Kemnitz$11,486,212
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsRunningCostProductionEscherichia ColiGenomicsFermentationGenomeAntibodiesAntigensCarrier ProteinsInterestToxinCross Reacting Material 197Pharmacologic SubstanceIndustryTechnologyScale UpDesignFlasksEndotoxinsProtein EngineeringConjugate VaccinesExperimental Study
Grant awards (21)
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies$1,030,000
R44 · FY2025 · AI
Development of a continuous microbial fermentation system using reduced genome E. coli that undergo programmed autolysis and generate nuclease post-production for the manufacture of biopharmaceuticals$937,537
R44 · FY2025 · GM · contact PI
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies$1,020,000
R44 · FY2024 · AI
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies$1,000,000
R44 · FY2023 · AI
Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture$961,744
R44 · FY2022 · AI
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain$1,000,000
R44 · FY2021 · AI
Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture$944,508
R44 · FY2021 · AI
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain$1,000,000
R44 · FY2020 · AI
Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture$1,000,000
R44 · FY2020 · AI
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain$1,000,000
R44 · FY2019 · AI
Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomicsâ reduced genome E. coli strains$706,927
R44 · FY2018 · AI
Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomicsâ reduced genome E. coli strains$877,755
R44 · FY2017 · AI
Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomicsâ reduced genome E. coli strains$154,222
R44 · FY2017 · AI
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain$728,655
R44 · FY2015 · AI
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain$732,955
R44 · FY2014 · AI
Nicotine and Gene Expression in Adolescent Brain$246,487
R01 · FY2006 · DA · contact PI
Nicotine and Gene Expression in Adolescent Brain$252,483
R01 · FY2005 · DA
Nicotine and Gene Expression in Adolescent Brain$252,545
R01 · FY2004 · DA
GENE EXPRESSION PROFILE IN RESPONSE TO DRUG PAIRED CUES$288,000
R01 · FY2002 · DA
GENE EXPRESSION PROFILE IN RESPONSE TO DRUG PAIRED CUES$284,480
R01 · FY2001 · DA
GENE EXPRESSION PROFILE IN RESPONSE TO DRUG PAIRED CUES$288,000
R01 · FY2000 · DA